For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
The Latest on: Cancer drug delivery
via Google News
The Latest on: Cancer drug delivery
- Moderna Shares Extend Gains as Jim Cramer Talks About Potential Cancer Vaccineon February 26, 2021 at 11:45 am
TheStreet's founder, Jim Cramer, says Moderna is working on the development of a messenger-RNA based vaccine against certain forms of cancer.
- Insights on the Exosomes Global Market to 2026 - Increasing Prevalence of Cancer is Driving Growth - ResearchAndMarkets.comon February 26, 2021 at 4:09 am
The “Exosomes Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)” report has been added to ResearchAndMarkets.com’s offering. The exosome market is projected to register a CAGR of ...
- Targeted drug delivery system more effective to treat cancer cells Scientists News Todayon February 26, 2021 at 1:04 am
Chennai: Glioblastoma multiforme (also called glioblastoma) is the most common and aggressive form of primary brain tumour and it's the most common type of malignant brain tumour among adults. Now ...
- Fabrication of anionic dextran-coated micelles for aptamer targeted delivery of camptothecin and survivin-shRNA to colon adenocarcinomaon February 25, 2021 at 7:01 am
In this study, we synthesized PLA-PEI micelles which was co-loaded with an anticancer drug, camptothecin (CPT), and survivin-shRNA (sur-shRNA). The hydrophobic CPT was encapsulated in the core of the ...
- Brain targeted system for delivery of highly toxic anti-cancer drugon February 25, 2021 at 4:08 am
Targeted delivery of anti-cancer drug to a localised tumor site has shown to improve the effectiveness of treatment as it concentrates drug at their site of action, and thus reducing side effects at ...
- The Petri Dish: Beam's acquisition; cancer startup gets $95Mon February 25, 2021 at 1:30 am
Gene-editing startup acquires Atlanta biotech CRISPR gene-editing firm Beam Therapeutics acquired Guide Therapeutics, a developer of nonviral drug delivery vehicles for ... Hologic acquires cancer ...
- Targeted delivery of highly toxic anti-cancer drug to brain tumorson February 23, 2021 at 10:56 am
University of Houston biomedical researcher Sheeren Majd is reporting the development and testing of a new nano-carrier as a potential treatment to deliver highly toxic medicine to glioblastomas, the ...
- Celsion Surges as FDA Fast-Tracks Ovarian-Cancer Drugon February 22, 2021 at 7:17 am
Celsion shares jumped after the drugmaker received FDA Fast Track status for its Phase 2 treatment for advanced ovarian cancer.
- Investors pour $8M into Raleigh medical device startup; its drug delivery tech traces roots to UNC-CHon February 19, 2021 at 12:15 pm
Advanced Chemotherapy Technologies (ACT), a medical device startup developing a way to improve the treatment of pancreatic cancer, has added $2.5 million in funding to support clinical testing of its ...
via Bing News